Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647972 · ClinicalTrials.gov registry record · Phase 1
Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00647972: Clinical Trial Phase 1 study, sponsored by Mylan Pharmaceuticals.
NCT00647972 is a Phase 1 study that was terminated before completion, run by Mylan Pharmaceuticals. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00647972, a Phase 1 study, was terminated before completion, sponsored by Mylan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan olanzapine 20 mg tablets to Eli Lilly Zyprexa® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fasting conditions.
Interventions
- DRUG Olanzapine Tablets 20 mg
- DRUG Zyprexa® Tablets 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2003-05 |
| Phase | Phase 1 |
Why NCT00647972 stopped before completion
NCT00647972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Olanzapine Tablets 20 mg is the first listed.
NCT00647972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00647972 about?
NCT00647972 is a clinical study titled "Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg". The objective of this study was to investigate the bioequivalence of Mylan olanzapine 20 mg tablets to Eli Lilly Zyprexa® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fasting conditions.
What is the current status of trial NCT00647972?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2003-05.
What interventions are being tested in trial NCT00647972?
The interventions under investigation include: Olanzapine Tablets 20 mg (DRUG), Zyprexa® Tablets 20 mg (DRUG).
Who is sponsoring clinical trial NCT00647972?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00647972's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia